Skip to main content

Camurus (SE)

Camurus AB is a Swedish research-based pharmaceutical company specializing in the development and commercialization of long-acting medicines for serious and chronic conditions. The company utilizes its proprietary FluidCrystal delivery technology to convert active pharmaceutical ingredients into long-acting subcutaneous depot formulations. Its core commercial product, Buvidal, is a long-acting buprenorphine depot treatment for opioid dependence, marketed globally under license agreements and direct commercial teams. Additional pipeline programs target central nervous system disorders, rare endocrine diseases, and oncology indications. Principal revenue drivers consist of direct pharmaceutical product sales, licensing royalties, milestone payments, and contract manufacturing agreements with commercial partners. Camurus holds a strong market position within long-acting addiction therapy across Europe and Australia. Headquartered in Lund, Sweden, the company's common shares are publicly listed and traded on Nasdaq Stockholm under the ticker CAMX.

37 of the funds FundTelligence covers report a position in Camurus (SE).

Sector
Health Care
Country
Sweden
Funds holding it
37
Exposure themes
Addiction, Mental Health, Psychiatry

Funds holding Camurus (SE)

Showing the 8 largest of 37 funds holding it.

Loading...